Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

National Institute of Allergy and Infectious Diseases (NIAID)

28 clinical trials · 28 recruiting · NIH

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by National Institute of Allergy and Infectious Diseases (NIAID)

RECRUITINGPhase 3NCT04047628

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 15620 locations
Relapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
RECRUITINGPhase 1NCT07262983

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or...

Background: Autosomal dominant hyper-IgE syndrome (HIES), also called Job syndrome, is a genetic disorder that affects the immune system. It can cause skin and lung infections...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 201 location
Hyper IgE Syndrome From STAT3 MutationJob s SyndromeHIES+2
RECRUITINGPhase 2NCT07108387

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

This is a multi-center, randomized, open label study that will assess the efficacy and safety of ACTEMRA(R) or one of its FDA-approved biosimilars Tocilizumab (TCZ) maintenance...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 787 locations
Giant Cell Arteritis (GCA)
RECRUITINGNCT06136091

Protocol CAUSE-03 / CHEETAH

This is a one-year longitudinal, observational study of 250 urban children and adolescents with asthma and 60 without asthma, ages 6-17 years old. Participants with asthma will...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 3108 locations
Asthma
RECRUITINGNCT04582903

Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and...

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 50001 location
COVID-19 Infection
RECRUITINGNCT04052022

Paradoxical Tuberculosis Reactions in Patients Without HIV Infection

Background: Most people with tuberculosis (TB) feel better after starting treatment. But for some people, the opposite happens. They may feel better at first, but then suddenly...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 1402 locations
Tuberculosis
RECRUITINGNCT01212003

Training Protocol on the Natural History of Tuberculosis

Background: \- Tuberculosis (TB) is an infectious disease that affects numerous people worldwide. Researchers are interested in actively recruiting individuals with TB for...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 1501 location
Mycobacterium InfectionsTuberculosis, Multidrug-ResistantLatent Tuberculosis+2
RECRUITINGPhase 2NCT06192160

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 31520 locations
Pulmonary Tuberculosis
RECRUITINGPhase 2NCT05383742

Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a...

The purpose of this study is to compare a 6-month regimen of high-dose rifampicin (RIF), high-dose isoniazid (INH), linezolid (LZD), and pyrazinamide (PZA) versus the World Health...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 33018 locations
Tuberculous Meningitis
RECRUITINGPhase 2NCT05719441

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation...

A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 4820 locations
Acute HIV Infection
RECRUITINGPhase 1 / Phase 2NCT06071767

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute...

The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 3612 locations
HIV-1-infection
RECRUITINGNCT05078905

Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases

Background: Vaccines against SARS-CoV-2, the virus that causes COVID-19, have been highly effective against preventing severe disease. But the protective effects of these...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 12001 location
COVID-19VaccinationHealthy Volunteer
RECRUITINGNCT02639299

Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria...

Background: Malaria is a serious infection caused by a parasite. People get malaria when an infected mosquito bites them. Malaria can cause major health and social problems in...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 15001 location
Malaria
RECRUITINGNCT00001645

Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection

The purpose of this study is to evaluate, treat and follow patients with parasitic infections. People with a known or suspected parasitic infection who are at least 1 year old...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 8001 location
MalariaIntestinal WormsGI Protozoa+2
RECRUITINGNCT02471378

Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates

Background: \- Malaria is a disease that affects many people in African countries. It is caused by germs that are spread by mosquito bites. It can be fatal if not diagnosed and...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 74761 location
Malaria
RECRUITINGPhase 2NCT07060508

L9LS in Women of Childbearing Potential in Mali

Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in a Randomized, Double-Blind, Placebo-Controlled Trial of Women of Childbearing Potential...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 2903 locations
Malaria
RECRUITINGNCT06468319

Pregnancy Registry in Mali

This registry will assess pregnancy outcomes through demographic surveillance and prospective data collection at a health facility in Kalifabougou, Mali.

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 95001 location
MalariaPregnancy Related
RECRUITINGNCT03937817

Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

Background: Blood disorders like sickle cell disease and malaria affect many people around the world. Researchers want to learn more about blood disorders. To do this, they need...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 3001 location
Alpha and Beta ThalassemiaSickle Cell DiseaseMalaria+1
RECRUITINGNCT01168271

Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early...

Malaria caused by Plasmodium falciparum continues to be a global problem with devastating consequences. A greater understanding of the immunologic and parasitologic factors...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 150002 locations
Malaria
RECRUITINGPhase 1NCT06607003

Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax...

Background: Malaria is a disease caused by parasites transmitted to people by mosquitoes. Around the world, there were 241 million cases and 627,000 deaths from malaria in 2020....

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 3001 location
Malaria
RECRUITINGNCT04772170

Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

Background: Respiratory viruses circulate throughout the year and around the globe. Wearable and sensor devices, like smartwatches, may be able to help monitor infectious...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 10001 location
InfluenzaRespiratory VirusCoronavirus
RECRUITINGPhase 1NCT07110532

pH1N1 Blinded Challenge Study

This protocol describes a clinical trial to develop and validate a Controlled Human Infection Model (CHIM) for influenza A/Arkansas/08/2020 (pH1N1). The study is designed to...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 1802 locations
Influenza
RECRUITINGNCT01386424

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

Background: * The Laboratory of Infectious Diseases (LID) Clinical Studies Unit (CSU) enrolls healthy volunteers into clinical studies to study infectious diseases. * Viruses can...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 50001 location
ZikaInfluenza
RECRUITINGPhase 1NCT07169318

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

A randomized, double-blind, placebo-controlled Phase 1 study conducted at a single center with approximately 78 healthy adults aged 18-59 years. Part 1 Single Ascending Dose (SAD)...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 781 location
Influenza
RECRUITINGPhase 2NCT07215858

BPL-1357 Against H1N1 Influenza Virus Challenge

Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 1292 locations
InfluenzaHuman
RECRUITINGPhase 2NCT05947071

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 3128 locations
Immunization; InfectionTransplantation InfectionInfluenza
RECRUITINGPhase 1NCT07111078

Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults

Background: Influenza (flu) is a contagious respiratory illness caused by viruses. Flu symptoms can range from mild to severe, and the illness can be fatal. Vaccines help the...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 561 location
Influenza PreventionPandemic Influenza Prevention
RECRUITINGNCT05266222

Respiratory Virus Sampling and Repository

Background: Respiratory viruses, like the flu or COVID-19, cause significant illness and death worldwide. Researchers want to collect samples from people with respiratory virus...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 200002 locations
InfluenzaCOVID-19